Uterine Fibroid Embolization (UFE) Gains Approval for Safety and Efficacy

Strategic Insights -

A significant breakthrough in the treatment of uterine fibroids has been announced by the Interventional Procedures Advisory Committee (IPAC) of the National Institute for Clinical Excellence (NICE). Uterine fibroid embolization (UFE), a less-invasive procedure, has been deemed safe and effective for treating fibroids, offering an alternative to traditional treatments such as pharmaceutical therapy, hysterectomy, or myomectomy. According to the committee, UFE can significantly reduce symptoms of heavy menstrual bleeding, pressure, and bulk-related issues, as well as alleviate pain, making it an attractive option for women suffering from this condition.

Key Takeaways:

  • UFE is a treatment for uterine fibroids, which are noncancerous growths that develop in the muscular wall of the uterus or cervix, affecting up to 25% of women of child-bearing age.
  • The growths can cause heavy menstrual bleeding (menorrhagia), pressure and bulk-related symptoms, and significant pain.
  • Traditional treatments include pharmaceutical therapy, hysterectomy, or myomectomy, but UFE offers an alternative that generally spares the uterus in women with symptomatic uterine fibroids.
  • Boston Scientific has developed the Contour SE embolic agent and the Renegade Hi-Flo, which are used by interventional radiologists in the UFE procedure.
  • IPAC has confirmed the safety and efficacy of UFE, making it a viable option for women seeking treatment for uterine fibroids.
  • The average length of hospital stay following the procedure is 1 night, compared to a typical post-hysterectomy hospital stay of 2-3 days.
  • Approximately 50,000 UFE procedures have been performed globally to date.

Statistics:

  • Up to 25% of women of childbearing age develop uterine fibroids.
  • Over 50,000 UFE procedures have been performed globally to date.
  • The average length of hospital stay following the UFE procedure is 1 night.
  • Traditional treatments for uterine fibroids can result in hospital stays of 2-3 days.

Sources:

  • NewsRx.com & NewsRx.net, "Boston Scientific Welcomes Uterine Fibroid Embolization (UFE) Safety and Efficacy Approval by NICE", dated NOV 29, 2004